Zobrazeno 1 - 10
of 94
pro vyhledávání: ''
Autor:
Ladislav Merta, Natalia Torrealba, Jaroslav Truksa, Jan Stursa, Jiri Neuzil, Lukas Werner, Daniel Rösel, Veronika Tomkova, Kristyna Blazkova, Jan Brábek, Sandra Lettlova, Sukanya Balkrishna Jadhav, Miroslava Kari Adamcová, Cristian Sandoval-Acuña
Publikováno v:
Cancer Research. 81:2289-2303
Deferoxamine (DFO) represents a widely used iron chelator for the treatment of iron overload. Here we describe the use of mitochondrially targeted deferoxamine (mitoDFO) as a novel approach to preferentially target cancer cells. The agent showed mark
Autor:
Lei Bi, Fuqiong Zhou, Peng Meng, Bo Tang, Yidan Ren, Yunshan Wang, Yu-Cui Jiang, Weiping Chen, Qin Wang, Chuanxin Wang, Maoxiao Feng, Yuli Wang, Feiyan Chen, Qinlian Jiao, Lutao Du
Publikováno v:
Cancer Research. 81:2015-2028
Hepatocellular carcinoma (HCC) contains a subset of cancer stem cells (CSC) that cause tumor recurrence, metastasis, and chemical resistance. Histone deacetylase 11 (HDAC11) mediates diverse immune functions and metabolism, yet little is known about
Autor:
Guohua Zhang, James Z. Zhu, Min Li, Yan Zuo, Jeffrey A. Frost, Zicheng Zhang, Yi-Ping Li, Thomas K. Sin
Publikováno v:
Cancer Res
Cancer-associated cachexia, characterized by muscle wasting, is a lethal metabolic syndrome without defined etiology or established treatment. We previously found that p300 mediates cancer-induced muscle wasting by activating C/EBPβ, which then upre
Autor:
Xixi Cao, Jamunarani Veeraraghavan, Shunqiang Li, Martin Shea, Lanfang Qin, Ying Tan, Susan G. Hilsenbeck, Xian Wang, Xiaosong Wang, Yiheng Hu, Jin-Ah Kim, Ling Lin, Tamika Mitchell, Rachel Schiff, Chia Chia Liu, Suet Kee Loo, Matthew J. Ellis, Sanghoon Lee
Publikováno v:
Clin Cancer Res
Purpose: Endocrine resistance remains a major clinical challenge in estrogen receptor (ER)–positive breast cancer. Despite the encouraging results from clinical trials for the drugs targeting known survival signaling, relapse is still inevitable. T
Autor:
Salvatore Siena, Daniel Moya-Rull, Andrea Sartore-Bianchi, Emanuele Rausa, Annalisa Petrelli, Annunziata Gloghini, Brian M. Alexander, Daniela Conticelli, Asa Dahle-Smith, Sara Erika Bellomo, Filippo Pietrantonio, J. Lee, Siraj M. Ali, Giovanni Sgroi, Vincent A. Miller, Federica Morano, Salvatore Corallo, Uberto Fumagalli, Silvia Giordano, Maria Di Bartolomeo, Caterina Marchiò, Giovanni de Manzoni, Anna Sapino, Antonino Sottile, Stefano De Pascale, Gian Luca Baiocchi, Laura D'Errico, Silvia Marsoni, Rossella Reddavid, Simona Corso, Michele Prisciandaro, Stefania Durando, Zosia Miedzybrodzka, Cristina Migliore, Alexa B. Schrock, Russell D. Petty, Maria Apicella, Jeffrey S. Ross, Maurizio Degiuli, Sarah Molfino, Maria Bencivenga, Stefano Ughetto
Publikováno v:
Clinical Cancer Research. 27:3126-3140
Purpose: Gastric and gastroesophageal adenocarcinomas represent the third leading cause of cancer mortality worldwide. Despite significant therapeutic improvement, the outcome of patients with advanced gastroesophageal adenocarcinoma is poor. Randomi
Publikováno v:
Molecular Cancer Therapeutics. 20:655-664
Doxorubicin and other anthracycline derivatives are frequently used as part of the adjuvant chemotherapy regimen for triple-negative breast cancer (TNBC). Although effective, doxorubicin is known for its off-target and toxic side effect profile, part
Autor:
Zahid H. Siddik, Bangxing Hong, Uksha Saini, David E. Cohn, Anil K. Sood, Guangsheng Pei, Guangan He, Zhongming Zhao, Yuanqing Yan, Karuppaiyah Selvendiran, Valerie Chapa, Balveen Kaur, Ji Young Yoo, Puneet Modgil
Publikováno v:
Clin Cancer Res
Purpose:Here we investigated the impact of oncolytic herpes simplex virus (HSV) treatment on cisplatin sensitivity of platinum-resistant ovarian cancer, and the impact of the combination on immunotherapy.Experimental Design:Therapeutic efficacy of th
Autor:
Carsten Sticht, Carolin Mogler, Olga Ermakova, Fabian Rose, Stefan Thomann, Eduard Ryschich, Carolina De La Torre, Daniel Kazdal, Kai Breuhahn, Claudia R. Ball, Norbert Gretz, Stephanie Roessler, Simone Marquard, Sarah Fritzsche, Peter Schirmacher, S Weiler, Teng Wei, Eugen Rempel, Hanno Glimm, Marcell Tóth
Publikováno v:
Cancer Research. 80:5502-5514
The oncogene yes-associated protein (YAP) controls liver tumor initiation and progression via cell extrinsic functions by creating a tumor-supporting environment in conjunction with cell autonomous mechanisms. However, how YAP controls organization o
Autor:
Kyle B. Williams, Lauren J. Mills, David A. Largaespada, Kelsie L. Becklin, Joseph J. Peterson, Nicholas J. Slipek, Garrett M. Draper, Susan K. Rathe, Kenta Yamamoto, Kanut Laoharawee, Emily J. Pomeroy, Natalie Stratton, Juan E. Abrahante, Wendy A. Hudson, Branden S. Moriarity, Margaret R. Crosby, Branden A. Smeester, Eric P. Rahrmann, Alex T. Larsson
Publikováno v:
Mol Cancer Ther
We previously identified ZNF217 as an oncogenic driver of a subset of osteosarcomas using the Sleeping Beauty (SB) transposon system. Here, we followed up by investigating the genetic role of ZNF217 in osteosarcoma initiation and progression through
Autor:
David F. Jarrard, Tariq A. Khemees, Shivashankar Damodaran, Bing Yang, Mikolaj Filon, Dmitry Malin, Tyler Etheridge, Kyle A. Richards, Adam Schultz, Vincent L. Cryns, Joseph Gawdzik
Publikováno v:
Molecular Cancer Therapeutics. 19:2278-2287
The initiation of androgen-deprivation therapy (ADT) induces susceptibilities in prostate cancer cells that make them vulnerable to synergistic treatment and enhanced cell death. Senescence results in cell-cycle arrest, but cells remain viable. In th